Compounds > erlotinib hydrochloride
Page last updated: 2024-09-05

erlotinib hydrochloride and Mucositis, Oral

erlotinib hydrochloride has been researched along with Mucositis, Oral in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Biondo, A; Cassier, PA; Chen, E; de Bono, JS; Minton, S; Molife, LR; Papadopoulos, KP; Patnaik, A; Siu, LL; Sullivan, DM; Tetteh, E; Tolcher, AW; Vitfell-Rasmussen, J; Yan, L; Zernhelt, AM1
Abdel-Rahman, O; Fouad, M1
Gao, H; Guo, W; Li, J; Liu, X; Qin, H; Qu, L; Tang, C; Wang, H; Wang, W; Wei, X1
Carroll, WR; Clemons, L; Deep, NL; Desmond, R; Heath, CH; Magnuson, JS; Nabell, L; Rosenthal, EL; Spencer, S1
Bennouna, J; Chamorey, E; Douillard, JY; Etienne-Grimaldi, MC; Follana, P; Francois, E; Mari, V; Michel, C; Milano, G; Renée, N; Senellart, H1

Reviews

1 review(s) available for erlotinib hydrochloride and Mucositis, Oral

ArticleYear
Risk of selected gastrointestinal toxicities in patients with advanced non-small cell lung cancer receiving erlotinib: a systematic review and meta-analysis.
    Expert review of anticancer therapy, 2015, Volume: 15, Issue:4

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Stomatitis

2015

Trials

4 trial(s) available for erlotinib hydrochloride and Mucositis, Oral

ArticleYear
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.
    Journal of hematology & oncology, 2014, Jan-03, Volume: 7

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Exanthema; Fatigue; Febrile Neutropenia; Female; Heterocyclic Compounds, 3-Ring; Humans; Male; Middle Aged; Nausea; Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-akt; Quinazolines; Stomatitis; Taxoids; Tinnitus; Treatment Outcome; Young Adult

2014
[Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].
    Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2012, Volume: 15, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Stomatitis; Treatment Outcome

2012
Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma.
    International journal of radiation oncology, biology, physics, 2013, Apr-01, Volume: 85, Issue:5

    Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Disease-Free Survival; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiodermatitis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Skin Neoplasms; Stomatitis

2013
Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study.
    Chemotherapy, 2012, Volume: 58, Issue:5

    Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Deoxycytidine; Diarrhea; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Half-Life; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Quinazolines; Stomatitis; Vomiting

2012